The X-Linked Inhibitor of Apoptosis Protein Inhibitor Embelin Suppresses Inflammation and Bone Erosion in Collagen Antibody Induced Arthritis Mice

Mediators of Inflammation

Volumn 2015, Issue , 2015, Pages

  Dharmapatni, Anak A S S K ^a   Cantley, Melissa D ^a   Marino, Victor ^a   Perilli, Egon ^b   Crotti, Tania N ^a   Smith, Malcolm D ^c,d   Haynes, David R ^a  

^a UNIVERSITY OF ADELAIDE   (Australia)

^b Flinders University   (Australia)

^c FLINDERS UNIVERSITY   (Australia)

^d Department of Rheumatology Flinders Medical Centre Flinders University ^*  (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

MUS;

ACID PHOSPHATASE; ACID PHOSPHATASE TARTRATE RESISTANT ISOENZYME; ACP5 PROTEIN, MOUSE; BENZOQUINONE DERIVATIVE; EMBELIN; ISOENZYME; X LINKED INHIBITOR OF APOPTOSIS;

ANIMAL; ANTAGONISTS AND INHIBITORS; ARTHRITIS, EXPERIMENTAL; IMMUNOLOGY; INFLAMMATION; METABOLISM; MOUSE; OSTEOLYSIS;

ACID PHOSPHATASE; ANIMALS; ARTHRITIS, EXPERIMENTAL; BENZOQUINONES; BONE RESORPTION; INFLAMMATION; ISOENZYMES; MICE; TARTRATE-RESISTANT ACID PHOSPHATASE; X-LINKED INHIBITOR OF APOPTOSIS PROTEIN;

EID: 84939825981     PISSN: 09629351     EISSN: 14661861     Source Type: Journal    
DOI: 10.1155/2015/564042     Document Type: Article

References (50)

1. E. M. Gravallese, C. Manning, A. Tsay et al., "Synovial tissue in rheumatoid arthritis is a source of osteoclast differentiation factor," Arthritis & Rheumatology, vol. 43, no. 2, pp. 250-258, 2000.
2. R. M. Pope, "Apoptosis as a therapeutic tool in rheumatoid arthritis," Nature Reviews Immunology, vol. 2, no. 7, pp. 527-535, 2002.
3. W. Li, Z. Liu, G. Zhuang et al., "Anti-DR5mAb ameliorate adjuvant arthritis rats through inducing synovial cells apoptosis," Experimental Biology and Medicine, vol. 234, no. 12, pp. 1468-1476, 2009.
4. N. Odani-Kawabata, M. Takai-Imamura, O. Katsuta et al., "ARG098, a novel anti-human Fas antibody, suppresses synovial hyperplasia and prevents cartilage destruction in a severe combined immunodeficient-HuRAg mouse model," BMCMusculoskeletal Disorders, vol. 11, article 221, 2010.
5. A. Ashkenazi and V. M. Dixit, "Apoptosis control by death and decoy receptors," Current Opinion in Cell Biology, vol. 11, no. 2, pp. 255-260, 1999.
6. G. S. Salvesen and C. S. Duckett, "IAP proteins: blocking the road to death's door," Nature Reviews Molecular Cell Biology, vol. 3, no. 6, pp. 401-410, 2002.
7. B. W. Richter and C. S. Duckett, "The IAP proteins: caspase inhibitors and beyond," Science's STKE, vol. 2000, no. 44, p. PE1, 2000.
8. Y. Che, F. Ye, R. Xu et al., "Co-expression of XIAP and cyclin D1 complex correlates with a poor prognosis in patients with hepatocellular carcinoma," The American Journal of Pathology, vol. 180, no. 5, pp. 1798-1807, 2012.
9. Z. Cao, R. Zhang, J. Li et al., "X-linked inhibitor of apoptosis protein (XIAP) regulation of cyclin D1 protein expression and cancer cell anchorage-independent growth via its E3 ligasemediated protein phosphatase 2A/c-Jun axis," The Journal of Biological Chemistry, vol. 288, no. 28, pp. 20238-20247, 2013.
10. D. Conte, M. Holcik, C. A. Lefebvre et al., "Inhibitor of apoptosis protein cIAP2 is essential for lipopolysaccharide-induced macrophage survival," Molecular and Cellular Biology, vol. 26, no. 2, pp. 699-708, 2006.
11. M. J. M. Bertrand, K. Doiron, K. Labbé, R. G. Korneluk, P. A. Barker, and M. Saleh, "Cellular inhibitors of apoptosis cIAP1 and cIAP2 are required for innate immunity signaling by the pattern recognition receptors NOD1 and NOD2," Immunity, vol. 30, no. 6, pp. 789-801, 2009.
12. L. D. Bauler, C. S. Duckett, and M. X. D. O'Riordan, "XIAP regulates cytosol-specific innate immunity to listeria infection," PLoS Pathogens, vol. 4, no. 8, Article ID e1000142, 2008.
13. K. Yamaguchi, S.-I. Nagai, J. Ninomiya-Tsuji et al., "XIAP, a cellular member of the inhibitor of apoptosis protein family, links the receptors to TAB1-TAK1 in the BMP signaling pathway," The EMBO Journal, vol. 18, no. 1, pp. 179-187, 1999.
14. S. B. Reffey, J. U. Wurthner, W. T. Parks, A. B. Roberts, and C. S. Duckett, "X-linked inhibitor of apoptosis protein functions as a cofactor in transforming growth factor-beta signaling," The Journal of Biological Chemistry, vol. 276, no. 28, pp. 26542-26549, 2001.
15. M. Lu, S.-C. Lin, Y. Huang et al., "XIAP induces NF-κB activation via the BIR1/TAB1 interaction and BIR1 dimerization," Molecular Cell, vol. 26, no. 5, pp. 689-702, 2007.
16. A. A. S. S. K. Dharmapatni, M. D. Smith, D. M. Findlay et al., "Elevated expression of caspase-3 inhibitors, survivin and xIAP correlates with low levels of apoptosis in active rheumatoid synovium," Arthritis Research and Therapy, vol. 11, no. 1, article R13, 2009.
17. M. D. Smith, H. Weedon, V. Papangelis, J. Walker, P. J. Roberts-Thomson, and M. J. Ahern, "Apoptosis in the rheumatoid arthritis synovialmembrane: modulation by disease-modifying anti-rheumatic drug treatment," Rheumatology, vol. 49, no. 5, pp. 862-875, 2010.
18. M. Bokarewa, S. Lindblad, D. Bokarew, and A. Tarkowski, "Balance between survivin, a key member of the apoptosis inhibitor family, and its specific antibodies determines erosivity in rheumatoid arthritis," Arthritis research & therapy., vol. 7, no. 2, pp. R349-R358, 2005.
19. J. K. Ahn, J.-M. Oh, J. Lee et al., "Increased extracellular survivin in the synovial fluid of rheumatoid arthritis patients: fibroblastlike synoviocytes as a potential source of extracellular survivin," Inflammation, vol. 33, no. 6, pp. 381-388, 2010.
20. A. Isgren, K. Forslind, M. Erlandsson et al., "High survivin levels predict poor clinical response to infliximab treatment in patients with rheumatoid arthritis," Seminars in Arthritis and Rheumatism, vol. 41, no. 5, pp. 652-657, 2012.
21. B. A. Mayer, M. Rehberg, A. Erhardt et al., "Inhibitor of apoptosis proteins as novel targets in inflammatory processes," Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 31, no. 10, pp. 2240-2250, 2011.
22. M. Chitra, E. Sukumar, V. Suja, and C. S. Shyamala Devi, "Antitumour, anti-inflammatory and analgesic property of embelin, a plant product," Chemotherapy, vol. 40, no. 2, pp. 109-113, 1994.
23. S. Mahendran, S. Badami, S. Ravi, B. S. Thippeswamy, and V. P. Veerapur, "Synthesis and evaluation of analgesic and antiinflammatory activities of most active free radical scavenging derivatives of embelin-a structure-activity relationship," Chemical and Pharmaceutical Bulletin, vol. 59, no. 8, pp. 913-919, 2011.
24. G. Kalyan Kumar, R. Dhamotharan, N. M. Kulkarni, M. Y. A. Mahat, J. Gunasekaran, and M. Ashfaque, "Embelin reduces cutaneous TNF-α level and ameliorates skin edema in acute and chronic model of skin inflammation in mice," European Journal of Pharmacology, vol. 662, no. 1-3, pp. 63-69, 2011.
25. Z. Nikolovska-Coleska, L. Xu, Z. Hu et al., "Discovery of embelin as a cell-permeable, small-molecular weight inhibitor of XIAP through structure-based computational screening of a traditional herbal medicine three-dimensional structure database," Journal of Medicinal Chemistry, vol. 47, no. 10, pp. 2430-2440, 2004.
26. M. Xu, J. Cui, H. Fu, P. Proksch, W. Lin, and M. Li, "Embelin derivatives and their anticancer activity through microtubule disassembly," Planta Medica, vol. 71, no. 10, pp. 944-948, 2005.
27. J. Chen, Z. Nikolovska-Coleska, G. Wang, S. Qiu, and S. Wang, "Design, synthesis, and characterization of new embelin derivatives as potent inhibitors of X-linked inhibitor of apoptosis protein," Bioorganic and Medicinal Chemistry Letters, vol. 16, no. 22, pp. 5805-5808, 2006.
28. S. Reuter, S. Prasad, K. Phromnoi, R. Kannappan, V. R. Yadav, and B. B. Aggarwal, "Embelin suppresses osteoclastogenesis induced by receptor activator of NF-κB ligand and tumor cells in vitro through inhibition of the NF-κB cell signaling pathway," Molecular Cancer Research, vol. 8, no. 10, pp. 1425-1436, 2010.
29. M.D. Cantley, D.R. Haynes, V. Marino, and P.M. Bartold, "Preexisting periodontitis exacerbates experimental arthritis in a mouse model," Journal of Clinical Periodontology, vol. 38, no. 6, pp. 532-541, 2011.
30. J. D. Peterson, T. P. LaBranche, K. O. Vasquez et al., "Optical tomographic imaging discriminates between diseasemodifying anti-rheumatic drug (DMARD) and non-DMARD efficacy in collagen antibody-induced arthritis," Arthritis Research and Therapy, vol. 12, no. 3, article R105, 2010.
31. B. Bolon, M. Stolina, C. King et al., "Rodent preclinical models for developing novel antiarthritic molecules: comparative biology and preferred methods for evaluating efficacy," Journal of Biomedicine and Biotechnology, vol. 2011, Article ID 569068, 21 pages, 2011.
32. E. Perilli, V. Le, B. Ma, P. Salmon, K. Reynolds, and N. L. Fazzalari, "Detecting early bone changes using in vivo micro-CT in ovariectomized, zoledronic acid-treated, and shamoperated rats," Osteoporosis International, vol. 21, no. 8, pp. 1371-1382, 2010.
33. K. S. Nandakumar, L. Svensson, and R. Holmdahl, "Collagen type II-specific monoclonal antibody-induced arthritis in mice: description of the disease and the influence of age, sex, and genes," The American Journal of Pathology, vol. 163, no. 5, pp. 1827-1837, 2003.
34. M. S. BURSTONE, "Histochemical demonstration of acid phosphatases with naphthol," Journal of the National Cancer Institute, vol. 21, no. 3, pp. 523-539, 1958.
35. T. Akatsu, T. Tamura, N. Takahashi et al., "Preparation and characterization of a mouse osteoclast-like multinucleated cell population," Journal of Bone and Mineral Research, vol. 7, no. 11, pp. 1297-1306, 1992.
36. F. P. Van De Wijngaert and E. H. Burger, "Demonstration of tartrate-resistant acid phosphatase in un-decalcified, glycolmethacrylate-embedded mouse bone: a possible marker for (pre)osteoclast identification," Journal of Histochemistry and Cytochemistry, vol. 34, no. 10, pp. 1317-1323, 1986.
37. G. P. Harvey, T. R. Fitzsimmons, A. A. S. S. K. Dhamarpatni, C. Marchant, D. R. Haynes, and P. M. Bartold, "Expression of peptidylarginine deiminase-2 and -4, citrullinated proteins and anti-citrullinated protein antibodies in human gingiva," Journal of Periodontal Research, vol. 48, no. 2, pp. 252-261, 2013.
38. M. C. Kraan, M. D. Smith, H. Weedon, M. J. Ahern, F. C. Breedveld, and P. P. Tak, "Measurement of cytokine and adhesionmolecule expression in synovial tissue by digital image analysis," Annals of the Rheumatic Diseases, vol. 60, no. 3, pp. 296-298, 2001.
39. P. Sun, Y. Liu, X. Deng et al., "An inhibitor of cathepsin K, icariin suppresses cartilage and bone degradation in mice of collageninduced arthritis," Phytomedicine, vol. 20, no. 11, pp. 975-979, 2013.
40. B. S. Thippeswamy, S. Mahendran, M. I. Biradar et al., "Protective effect of embelin against acetic acid induced ulcerative colitis in rats," European Journal of Pharmacology, vol. 654, no. 1, pp. 100-105, 2011.
41. K. Kumar G., N. M. Kulkarni, and S. Honnegowda, "Embelin ameliorates dextran sodium sulfate-induced colitis in mice," International Immunopharmacology, vol. 11, no. 6, pp. 724-731, 2011.
42. N. Roy, Q. L. Deveraux, R. Takahashi, G. S. Salvesen, and J. C. Reed, "The c-IAP-1 and c-IAP-2 proteins are direct inhibitors of specific caspases," The EMBO Journal, vol. 16, no. 23, pp. 6914-6925, 1997.
43. R. Hu, K. Zhu, Y. Li et al., "Embelin induces apoptosis through down-regulation of XIAP in human leukemia cells," Medical Oncology, vol. 28, no. 4, pp. 1584-1588, 2011.
44. S.-Y. Park, S.-L. Lim, H.-J. Jang et al., "Embelin induces apoptosis in human Glioma cells through inactivating NF-κB," Journal of Pharmacological Sciences, vol. 121, no. 3, pp. 192-199, 2013.
45. F. Lange, E. Bajtner, C. Rintisch, K. S. Nandakumar, U. Sack, and R. Holmdahl, "Methotrexate ameliorates T cell dependent autoimmune arthritis and encephalomyelitis but not antibody induced or fibroblast induced arthritis," Annals of the Rheumatic Diseases, vol. 64, no. 4, pp. 599-605, 2005.
46. H. Harlin, S. B. Reffey, C. S. Duckett, T. Lindsten, and C. B. Thompson, "Characterization of XIAP-deficient mice," Molecular and Cellular Biology, vol. 21, no. 10, pp. 3604-3608, 2001.
47. L. M. Khachigian, "Collagen antibody-induced arthritis," Nature Protocols, vol. 1, no. 5, pp. 2512-2516, 2006.
48. C.-C. Chao, S.-J. Chen, I. E. Adamopoulos et al., "Structural, cellular, andmolecular evaluation of bone erosion in experimental models of rheumatoid arthritis: assessment by μcT, histology, and serum biomarkers," Autoimmunity, vol. 43, no. 8, pp. 642-653, 2010.
49. M. D. Silva, A. Savinainen, R. Kapadia et al., "Quantitative analysis of micro-CT imaging and histopathological signatures of experimental arthritis in rats," Molecular Imaging, vol. 3, no. 4, pp. 312-318, 2004.
50. I. L. Engvall, B. Svensson, A. Boonen, D. van der heijde, U. H. Lerner, and I. Hafström, "Low-dose prednisolone in early rheumatoid arthritis inhibits collagen type I degradation by matrix metalloproteinases as assessed by serum 1CTPA possible mechanism for specific inhibition of radiological destruction," Rheumatology (United Kingdom), vol. 52, no. 4, Article ID kes369, pp. 733-742, 2013.